FDA lifts clinical hold on Repros' Proellex

06/13/2010 | Bloomberg Businessweek

The FDA approved Repros Therapeutics' request to conduct another trial of Proellex for use in reducing menstrual bleeding associated with uterine fibroids and endometriosis, lifting a clinical hold that was placed on the drug candidate last year because of liver toxicity. The drugmaker will test lower doses of Proellex on 12 women in a 10-week study comparing the drug with placebo.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC